# SER150 vs Placebo in Diabetic Kidney Disease

> **NCT04881123** · PHASE2,PHASE3 · COMPLETED · sponsor: **Serodus AS** · enrollment: 20 (actual)

## Conditions studied

- Diabetic Kidney Disease

## Interventions

- **DRUG:** SER150
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04881123
- **Lead sponsor:** Serodus AS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-18
- **Primary completion:** 2024-06-06
- **Final completion:** 2024-06-06
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2024-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04881123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04881123, "SER150 vs Placebo in Diabetic Kidney Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04881123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*